Rory Edwards
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rory Edwards has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
A.B. Olawaiye
Department of Gynecologic Oncology, Magee-Womens Hospital of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA
1 shared publication- Amelle Shillington
Cincinnati Children's Hospital
1 shared publication Amy Makley
Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, 45267
1 shared publication- Brian C. Orr
Division of Gynecologic Oncology, Medical University of South Carolina, Hollings Cancer Center , Charleston, SC
1 shared publication - Colton Brown
Department of Pediatric General and Thoracic Surgery Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA
1 shared publication Craig Erickson
Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by Elsevier in Journal of Pediatric Surgery
- p. 163547
Cumulative incidence and risk factors for pediatric firearm reinjury: A two-center cohort study
- 16 October 2026
- Published by Elsevier in Journal of Pediatric Surgery
- p. 163547
Open AccessCumulative incidence and risk factors for pediatric firearm reinjury: A two-center cohort study
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Genetics
- Vol. 2025 (1) , 4501466
Dual Diagnosis of Fragile X Syndrome and DEPDC5‐Related Disorder Emphasizes DEPDC5’s Role Beyond Familial Epilepsy: A Case Report and Literature Review
Dep domain‐containing Protein 5 (DEPDC5), encoded by the gene DEPDC5, regulates the cell cycle by inhibiting the mTORC1 pathway in response to amino acid deficiency. Loss of function DEPDC5 variants are recognized to present as focal familial epilepsy; however, associations with comorbid brain malformations and neurodevelopmental disorders have also been reported. mTOR inhibitors were found to benefit DEPDC5‐knockout mice. Fragile X syndrome (FXS) is an X‐linked neurodevelopmental disorder caused by loss of function of FMR1, and females are expected to have milder neurodevelopmental presentations than males. The reported individual is a 17‐year‐old female diagnosed with FXS at 1 year of age, but the severity of her neuropsychiatric symptoms prompted further genetic testing at age 14, revealing a likely pathogenic c.4307_4310del DEPDC5 variant. Following this diagnosis, she was started on the mTOR inhibitor sirolimus without significant clinical response. She has never been diagnosed with epilepsy; however, her DEPDC5 and FXS dual diagnosis was thought explanatory for her presentation. A review of 213 previously reported individuals with DEPDC5‐related disorder demonstrated that 15.2% of individuals do not have epilepsy, 24.3% have intellectual disability, and 33.8% have brain malformations. Her lack of response to sirolimus may represent the presence of a critical treatment window for mTOR inhibitors in neurodevelopmental disorders.
- 1 January 2025
- Published by Wiley in Case Reports in Genetics
- Vol. 2025 (1) , 4501466
Open AccessDual Diagnosis of Fragile X Syndrome and DEPDC5‐Related Disorder Emphasizes DEPDC5’s Role Beyond Familial Epilepsy: A Case Report and Literature Review
Dep domain‐containing Protein 5 (DEPDC5), encoded by the gene DEPDC5, regulates the cell cycle by inhibiting the mTORC1 pathway in response to amino acid deficiency. Loss of function DEPDC5 variants are recognized to present as focal familial epilepsy; however, associations with comorbid brain malformations and neurodevelopmental disorders have also been reported. mTOR inhibitors were found to benefit DEPDC5‐knockout mice. Fragile X syndrome (FXS) is an X‐linked neurodevelopmental disorder caused by loss of function of FMR1, and females are expected to have milder neurodevelopmental presentations than males. The reported individual is a 17‐year‐old female diagnosed with FXS at 1 year of age, but the severity of her neuropsychiatric symptoms prompted further genetic testing at age 14, revealing a likely pathogenic c.4307_4310del DEPDC5 variant. Following this diagnosis, she was started on the mTOR inhibitor sirolimus without significant clinical response. She has never been diagnosed with epilepsy; however, her DEPDC5 and FXS dual diagnosis was thought explanatory for her presentation. A review of 213 previously reported individuals with DEPDC5‐related disorder demonstrated that 15.2% of individuals do not have epilepsy, 24.3% have intellectual disability, and 33.8% have brain malformations. Her lack of response to sirolimus may represent the presence of a critical treatment window for mTOR inhibitors in neurodevelopmental disorders.
- Open Access
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , e469
PET-CT Directed IMRT-based Chemoradiation for Locally Advanced Vulvar Cancer - Analysis of Regional Recurrence Patterns
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , e469
Open AccessPET-CT Directed IMRT-based Chemoradiation for Locally Advanced Vulvar Cancer - Analysis of Regional Recurrence Patterns